Mechanism of action and selectivity
Rifamycins (specifically rifampicin) have a complex structure featuring a macrocyclic ring and belong to the ansamycin group. They exert a bactericidal effect by irreversibly binding to the beta subunit of bacterial DNA-dependent RNA polymerase.
- The drug does not interfere with the initiation of transcription, but blocks the elongation phase once the RNA chain reaches a length of 2–3 nucleotides.
- It is believed that the antibiotic molecule physically blocks the channel through which the growing RNA chain must emerge.
Selectivity of action is very high: mammalian RNA polymerases do not respond to therapeutic doses of the drug, and mitochondrial enzymes are inhibited only at extremely high concentrations that are unattainable during treatment.
Spectrum of activity and clinical use
The drugs possess a broad spectrum of activity. Their unique feature is the ability to destroy bacteria located inside phagosomes (acting on both extracellular and intracellular forms). Rapidly multiplying microorganisms are most sensitive to rifamycins:
- Mycobacteria: causative agents of tuberculosis (Mycobacterium tuberculosis) and leprosy (M. leprae).
- Intracellular pathogens: Brucella, Chlamydia, Legionella, Rickettsia.
- Gram-positive cocci: staphylococci, streptococci.
- Gram-negative cocci: meningococci, gonococci.
- Gram-negative bacilli: Escherichia coli (E. coli).
Clinically, rifampicin is used to treat tuberculosis, leprosy, brucellosis, and legionellosis, as well as for the specific prophylaxis of meningococcal infection. The drug can significantly slow down the reactivation of latent tuberculosis.
Resistance issues and pharmacokinetics
The main rule for using rifampicin in tuberculosis is a strict prohibition on monotherapy. Bacterial resistance develops rapidly due to mutations in the enzyme-binding site (at a frequency of 1 in 10⁶–10⁸ bacilli). Therefore, the drug is prescribed exclusively as part of combination therapy (for example, it exhibits synergy with isoniazid in vitro).
The elimination half-life of the drug is 2–5 hours. It is prescribed once daily or 3 times a week, administered orally (per os) or intravenously.
Rifampicin is a potent inducer of hepatic microsomal enzymes. It accelerates the metabolism and decreases the duration of action of many concurrently administered medications, including:
- Indirect anticoagulants (warfarin).
- Glucocorticoids.
- Oral contraceptives.
- Oral hypoglycemic agents.
Side effects
The drugs are generally well tolerated, but adverse reactions from various systems are possible:
- Specific: red-orange discoloration of biological fluids (sweat, tears, urine).
- Liver: elevated transaminases and bilirubin, jaundice, drug-induced hepatitis.
- Gastrointestinal tract: dyspepsia (nausea, vomiting, diarrhea, abdominal pain), oral candidiasis, pseudomembranous colitis.
- Blood: thrombocytopenic purpura, thrombocytopenia, leukopenia, acute hemolytic anemia.
- Kidneys: tubular necrosis, interstitial nephritis, acute renal failure.
- Allergic reactions: skin rash, pruritus, urticaria, angioedema, eosinophilia, drug fever (flu-like syndrome).
- Nervous system and special senses: visual disturbance, arthralgia.
- Upon intravenous administration: phlebitis, decreased blood pressure (if administered too rapidly).
Rifabutin as a second-line drug
Rifabutin is a semi-synthetic drug used as a second-line agent for tuberculosis. Its main differences from rifampicin are:
- Retains efficacy against certain strains of M. tuberculosis already resistant to rifampicin.
- Exhibits higher activity against the M. avium complex of atypical mycobacteria, which is relevant in HIV infection.
- Gastrointestinal absorption is independent of food intake (although overall bioavailability is lower).
- Binds to plasma proteins to a lesser extent.
- Has a significantly longer elimination half-life (32–67 hours).
- Is a weaker inducer of hepatic enzymes (CYP3A), therefore causing drug interactions less frequently.
Briefly: answers to topical questions
What are the clinical symptoms and causes of hepatotoxicity associated with rifampicin administration?
The clinical manifestations of rifampicin-induced hepatotoxicity are jaundice and drug-induced hepatitis, and the cause is the direct damaging effect of the drug on the organ.
Manifestations and causes of hepatotoxicity:
- Clinical symptoms — development of jaundice and drug-induced hepatitis.
- Laboratory findings — elevated transaminases and bilirubin levels.
- Cause — organotoxicity, representing a direct damaging effect of the antibiotic on the liver.
What hematological adverse effects can occur during rifampicin therapy?
The following hematological adverse effects may occur during rifampicin therapy:
- Thrombocytopenic purpura.
- Thrombocytopenia.
- Leukopenia.
- Acute hemolytic anemia.
To remember the adverse effects of rifampicin, use the red color association: "Red tears and urine (specific sign), red blood (hemolytic anemia, purpura), red liver (hepatitis), and red skin (allergic rash)."
Class and exam questions
At what stage does rifampicin block RNA synthesis?
The drug does not prevent transcription initiation. Blockade occurs at the elongation phase once 2–3 nucleotides are synthesized, by physically blocking the exit channel of the growing RNA chain.
Why cannot rifampicin be used as a monotherapy for tuberculosis?
During monotherapy, mycobacteria rapidly develop resistance due to a mutation in the binding site on RNA polymerase. Therefore, it is used only in combination therapy.
How does rifampicin affect the efficacy of oral contraceptives?
It is a potent inducer of hepatic microsomal enzymes (cytochrome P-450 system), thereby accelerating the metabolism of contraceptives and drastically reducing their efficacy.
What else to study on this topic
- Chemical structure of ansamycins and the role of the macrocyclic ring.
- Mechanisms of rifampicin synergy with isoniazid in vitro.
- Specifics of treating atypical mycobacterial infections in HIV-infected patients.
- Pathogenesis of pseudomembranous colitis associated with broad-spectrum antibiotic use.
Master the entire topic in the «Pharmacology» course
This is a summary. The course covers everything tested in classes and exams.
- Complete study guide on the topic «Rifamycins» and 5,304 other pages of the subject
- Assignments and quizzes after every topic — just like in a colloquium
- AI tutor answers questions on the topic anytime
- 116 video lessons on the subject
Other topics in the section "Antibacterial Chemotherapeutic Agents"
Free video lessons: pharmacologyShort lessons with study notes — no registration required.
Prepared by WhiteCoat Pro faculty in accordance with the medical school curriculum. For educational purposes only.